Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NNC9204-1706
- Development stage
- Phase 1
- Lead developer
- Novo Nordisk
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
NNC9204-1706 (also known as NN9423) is a peptide-based triple agonist targeting the glucagon-like peptide 1 receptor (GLP-1R), gastric inhibitory polypeptide receptor (GIPR), and glucagon receptor. It was developed by Novo Nordisk for the treatment of obesity and overweight. The drug was administered via subcutaneous injection and underwent phase 1 clinical trials to assess safety, tolerability, and pharmacokinetics in overweight or obese individuals. However, development was discontinued after phase 1 due to an inadequate safety profile characterized by dose-dependent increases in heart rate, reductions in reticulocyte count, increased markers of inflammation and hepatic disturbances, as well as impaired glucose tolerance at higher doses[1][2][3][6].
02
Targets
Beyond the preview
Go deeper on NNC9204-1706.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NNC9204-1706.